Hertility launches GYN-AI™ to help cut years-long diagnosis delays in women's health

Near 100% diagnostic precision across 18 fertility-related and gynaecological conditions

Hormonal health company Hertility has unveiled GYN-AI™, a patent-pending diagnostic tool it describes as “a moment of justice for women’s health”, promising to drastically cut diagnosis times for fertility and gynaecological conditions that can currently take years to identify.

Developed by Hertility’s team of scientists, clinicians, and data engineers, GYN-AI™ is trained on one of the largest datasets in women’s health: over one million Hertility Health Assessments and hundreds of thousands of blood results linked to confirmed clinical outcomes.

According to the company, the model achieves 98–99% diagnostic precision across 18 fertility-related and gynaecological conditions and can reduce diagnosis times for some from nine years to just seven days.

Dr Helen O’Neill, Founder and CEO of Hertility, said:

“I see this as a movement; and perhaps a moment of justice for women’s health. For too long, women have been dismissed, misdiagnosed, and left waiting years for answers about their own bodies. With GYN-AI™, we are changing that forever.

“Every algorithm has been trained on the lived experiences, symptoms, and data of over a million women: women who deserved faster care, earlier intervention, and to be believed. This tool will help clinicians deliver answers in days, not years, giving women back their time, their control, and in some cases, their chance to create life.

“This marks the beginning of a new era, one where women’s health is finally powered by data, intelligence, and compassion.”

Closing the data gap

For decades, women have faced unacceptable delays in receiving diagnoses for gynaecological and fertility-related conditions, with many waiting years, sometimes decades, for answers that should take days. Hertility says GYN-AI™ marks a turning point.

Until recently, women were largely excluded from clinical trials, leaving much of medical research - and the datasets used to train AI models - based on male physiology. This has meant that even the most sophisticated AI systems can be unreliable or unsafe when applied to women’s health.

GYN-AI™, by contrast, is built on Hertility’s own dataset, curated entirely from women’s health data. The company says this allows for diagnostic accuracy and safety that is unmatched in the field.

The new tool integrates across Hertility’s existing clinical services, including screening, diagnostic blood testing, ultrasound scanning, telemedicine consultations, prescriptions, IVF and egg freezing. The aim is to allow women to move seamlessly from assessment to diagnosis to treatment without delay - a full-service pathway that Hertility says “closes the loop on women’s healthcare like never before.”

Empowering clinicians, not replacing them

While the launch of AI tools in healthcare often prompts fears about automation replacing human expertise, Hertility emphasises that GYN-AI™ is designed to support, not supplant, clinicians.

Mr Srdjan Saso, Consultant Gynaecologist at Hertility, said:

“As a clinician, I have seen the damage that diagnostic delays cause physically, emotionally, and financially. GYN-AI™ is truly revolutionary in medicine - it allows us to detect potential issues earlier and with greater precision than ever before, guiding women to the right care pathway faster.

“This technology does not replace doctors; it empowers them. It gives us a clinical tool built on real-world data that helps us treat women sooner, more accurately, and more holistically.”

Hertility describes GYN-AI™ as the beginning of a “new clinical paradigm”, shifting women’s health from reactive to proactive care by combining science, compassion, and data intelligence. The company’s broader mission remains focused on closing the gender health gap through faster, more personalised diagnostics.